Omecamtiv mecarbil for heart failure: Unpacking the latest systematic review and meta-analysis
International Journal of Cardiology and Cardiovascular Diseases · 2024
DOI: 10.46439/cardiology.4.028 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Cardiology and Cardiovascular Diseases, 2024. Verfasst von Ramzi Ibrahim.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
In February 2023, a systematic review and meta-analysis of six randomized controlled trials (RCTs) with a total of 9,596 patients assessed the effectiveness and safety of omecamtiv mecarbil (OM) versus placebo in patients with heart failure with reduced left ventricular ejection fraction (HFrEF). HFrEF is a significant health problem associated with high morbidity and mortality worldwide. OM is a novel drug that targets cardiac myosin, a cytoskeletal motor protein responsible for converting chemical energy to mechanical force.
Zitieren
APA
Ibrahim, R. (2024). Omecamtiv mecarbil for heart failure: Unpacking the latest systematic review and meta-analysis. International Journal of Cardiology and Cardiovascular Diseases. https://doi.org/10.46439/cardiology.4.028
Vancouver
Ibrahim R. Omecamtiv mecarbil for heart failure: Unpacking the latest systematic review and meta-analysis. International Journal of Cardiology and Cardiovascular Diseases. 2024. doi:10.46439/cardiology.4.028
BibTeX
@article{Ibrahim2024,
author = {Ibrahim, Ramzi},
title = {Omecamtiv mecarbil for heart failure: Unpacking the latest systematic review and meta-analysis},
journal = {International Journal of Cardiology and Cardiovascular Diseases},
year = {2024},
doi = {10.46439/cardiology.4.028}
}
EUVIMED